BioGaia AB (publ) (STO:BIOG.B)

Sweden flag Sweden · Delayed Price · Currency is SEK
98.50
-0.20 (-0.20%)
At close: Dec 5, 2025
-8.37%
Market Cap 9.96B
Revenue (ttm) 1.46B
Net Income (ttm) 315.92M
Shares Out 101.16M
EPS (ttm) 3.12
PE Ratio 31.57
Forward PE 25.44
Dividend 6.90 (6.99%)
Ex-Dividend Date May 8, 2025
Volume 227,636
Average Volume 375,150
Open 98.85
Previous Close 98.70
Day's Range 97.50 - 99.05
52-Week Range 93.20 - 139.70
Beta 0.44
RSI 37.20
Earnings Date Feb 12, 2026

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablet... [Read more]

Sector Healthcare
Founded 1990
Employees 225
Stock Exchange Nasdaq Stockholm
Ticker Symbol BIOG.B
Full Company Profile

Financial Performance

In 2024, BioGaia AB's revenue was 1.42 billion, an increase of 9.73% compared to the previous year's 1.30 billion. Earnings were 351.39 million, a decrease of -3.82%.

Financial Statements

News

BioGaia AB (BIOGY) Q3 2025 Earnings Call Highlights: Strategic Growth Amidst Regional Challenges

BioGaia AB (BIOGY) Q3 2025 Earnings Call Highlights: Strategic Growth Amidst Regional Challenges

6 weeks ago - GuruFocus

Q3 2025 Biogaia AB Earnings Call Transcript

Q3 2025 Biogaia AB Earnings Call Transcript

6 weeks ago - GuruFocus

Q2 2025 Biogaia AB Earnings Call Transcript

Q2 2025 Biogaia AB Earnings Call Transcript

4 months ago - GuruFocus